Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg vs Pirtobrutinib in Relapsed/Refractory CLL or SLL
NCT06973187Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of tacabrutideg in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-Free Survival per Independent Review Committee. Started Sep 2025; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06973187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973187.